Apparent lack of prognostic value of MIB-1 index in anal carcinomas treated by radiotherapy. by Allal, A. S. et al.
British Joumal ofCancer(1998) 77(8), 1333-1336
© 1998 Cancer Research Campaign
Apparent lack of prognostic value of MIB-1 index in anal
carcinomas treated by radiotherapy
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Summary This study was conducted to investigate the influence of Mib-1 index on outcome in 55 patients with T1-4 anal carcinomas treated
radically by radiotherapy (RT) alone (24) or by concomitant chemo-radiotherapy (31). Median follow-up forsurviving patients was 94 months
(range 17-179 months). Tissue materials were obtained from pretreatment biopsies. A modified immunoperoxidase technique consisting of
microwave heating of routinely processed material was employed using the Mib-1 antibody (Immunotech, 1:50). The median Mib-1 index for
all patients was 53% (range 18-96%). Subgroups of patients with high vs low Mib-1 indices (separated by the median value) had statistically
similar outcomes regarding 5-year overall survival (64% vs 65% P = 0.7), locoregional control (77% vs 69%, P = 0.5) and disease-free
survival (73% vs 66%, P= 0.5). Moreover, no significant association was found between mean Mib-1 indices and various clinicopathological
parameters studied (age, sex, circumferential tumour extent, T-stage, N-stage and histological type). In conclusion, Mib-1 index failed to
predict the outcome of patients with anal carcinomas treated conservatively by radiotherapy with or without chemotherapy. It is noteworthy
that the median Mib-1 index observed in anal carcinomas in this study was among the highest yet reported for cancers of epithelial origin.
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Sphincter-conserving treatment based upon radiation therapy
(RT), often in association with chemotherapy, is now well estab-
lished as the standard first-line therapy forthe vast majority ofanal
carcinomas. Whereas conservative approaches yield a high rate of
local control, locoregional failure may occur in up to 30-35% of
patients treated with curative intent (Papillon and Montbarbon,
1987; Cummings et al, 1991; Allal et al, 1993). Besides clinical
tumour stage, no other reliable clinical or pathological prognostic
factors have yet been identified (Salmon et al, 1986; Goldmann et
al, 1987; Cummings et al, 1991; Touboul et al, 1994).
In the last decade, there has been great interest in tumour prolif-
eration and its relation to therapeutic outcome. Tumour cell kinetic
information has been obtained by a variety of methods, including
tritiated thymidine labelling, S-phase fraction by flow cytometry
and quantification of various proliferation-associated antigens.
Mib-l is a murine monoclonal antibody with the property of
reacting with the nuclear antigen Ki-67, which is expressed in all
phases of the cell cycle except GO' This antibody can be used in
formalin-fixed, paraffin-embedded specimens after microwave
treatment, thereby allowing the analysis to be carried out using
archival material (Gerdes et al, 1992). Mib-I antibody provides
nuclear staining of cells presumed to be proliferating in both
normal and neoplastic conditions, hence defining a Mib-l index.
Several recent reports have focused on the potential correlation
of Mib-1 index with clinical outcome in a variety of human
cancers. Mib-1 has been found to be of apparent prognostic value
forcertain tumours (Ng et al, 1995; Pinder et al, 1995; Chowdhury
et al, 1996; Wakimoto et al, 1996). However, little is known about
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the proliferative index of anal carcinomas, and no correlation of
Mib-l index with patient outcome has thus far appeared in the
literature. We thus undertook this retrospective study to determine
the Mib-I index in paraffin sections of archival materials from
anal carcinoma patients with long follow-up.
MATERIALS AND METHODS
The study population consisted of55 patients with anal carcinoma
treated with curative intent at the University Hospital of Geneva
between March 1976 and July 1993, for whom adequate paraffin-
embedded material had been retrieved for analysis. All patients
were treated primarily by radiation therapy, either alone (24) or
combined with chemotherapy (31). The diagnosis was established
by incisional biopsy in 45 cases and by excisional biopsy in ten
cases. All tumours were classified according to the 1987 staging
system of the Union Intemationale Contre le Cancer (UICC,
1987). Pretreatment characteristics of the patients are shown in
Table 1.
Treatment
Details of treatment have previously been published (Allal et al,
1993). Briefly, RT was generally delivered in a split course, the
first sequence consisting of wide-field extemal beam RT and the
second of a small-volume boost, most often with interstitial low
dose rate 1921r brachytherapy. The initial treatment was carried out
using megavoltage photons (6OCo or 6-18 MV X-rays) and always
included the primary tumour and clinically involved nodes with
wide margins. 'Prophylactic' irradiation of inguinal and pelvic
nodes was often carried out, according to the clinicaljudgement of
the treating physician. Extemal beam doses varied between 30 Gy
in ten fractions and 40 Gy in 20 fractions. The median boost dose
was 20 Gy. The median overall treatment time was 74 days.
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Table 1 Patient characteristics (55)
No. of patients (%)
Median age, years [range]
Male/female [ratio]
Tumour location
Canal ± anorectal junction
Margin
Canal + margin
Histological type
Keratinizing squamous
Basaloid and transitional
Clinical stage
Ti
T2
T3
T4
NO
N1-3
Nx
65 [42-90]
15/40 [0.37]
42 (76)
3 (6)
10 (18)
32 (58)
23 (42)
3 (5)
31 (56)
19 (35)
2 (4)
43 (78)
11 (20)
1 (2)
Thirty-one patients (56%) received concomitant chemotherapy.
Combined treatment was reserved initially for patients with
advanced stages and gradually extended to include almost all
patients, except for selected patients with very favourable tumours
or those in poor general condition. Generally chemotherapy
started on day I and consisted of one cycle of mitomycin-C
(10 mg m-2 intravenous bolus) and a 5-day continuous infusion
of 5-fluorouracil (600-800 mg m-2 day-1). Only four patients
received a second course of the same chemotherapy during the
boost treatment.
Immunohistochemical detection of Ki-67 antigen
All tissue materials were obtained from the pretreatment biopsies.
Forty-two (76%) ofthe specimens were obtained from the archival
files of the Pathology Department of the University Hospital of
Geneva and 13 from other laboratories. No apparent differences
were noted in the adequacy ofthe immunohistochemical detection
of Ki-67 antigen in the oldest stored material compared with that
ofthe most recent cases.
Buffered formalin-fixed, alcohol-dehydrated, xylene-cleared,
paraffin-embedded sections of tumour samples were stained with
haematoxylin and eosin for microscopic architectural evaluation.
A modified immunoperoxidase technique consisting ofmicrowave
heating of routinely processed material was performed using the
Mib-1 antibody (Immunotech, 1/50). Conventional 5-gm-thick
histological sections were mounted on to silane-coated slides,
dewaxed in xylene and rehydrated in a series of graded alcohols.
The slides were then immersed in 0.1% sodium citrate at pH 6,
incubated twice for 5 min in a microwave oven, then washed in
phosphate buffered saline (PBS) and placed in 5% normal goat
serum for 20 min before immunoperoxidase staining. Fresh-frozen
sections from infiltrating breast carcinoma stained with Ki-67 anti-
body were used as negative controls. All slides were studied using
a Leitz orthoplan microscope, equipped with a 40 x objective and
an eyepiece graticule. Microscopic fields were selected in the
higher labelling areas. Independently of intensity, all identifiable
nuclear staining was regarded as positive. For each case, one count
of 1000 cells was performed and Mib-l index was expressed as the
percentage of positive cells. Stromal and vascular cells, when
identified, were excluded from the counting.
Follow-up and statistical evaluation
Complete follow-up information was available for all patients.
Tumour persistence or recurrence in the anorectal area or the
perineal skin as well as regional nodal recurrences were consid-
ered as events in determining locoregional control rate, whereas
disease-free survival rate additionally took into account distant
metastases. Actuarial locoregional control, overall and disease-
free survival rates were calculated by the product-limit method
(Kaplan and Meier, 1958). The log-rank test was used to assess the
correlation of these end points with the Mib-1 index and the other
clinical (age, sex, circumferential tumour extent, T-stage, N-stage
and histological type) and therapeutic variables (addition of
chemotherapy, radiotherapy technique and overall treatmenttime).
The two-tailed t-test test was used to assess the correlation
between clinicopathological parameters and the mean values of
the Mib-l indices.
RESULTS
Overall results
At the last follow-up, 34 patients were alive, 20 had died, and one
was lost to follow-up at 106 months. Median follow-up for
surviving patients was 94 months (range 17-179 months). Sixteen
patients presented with one or more events. Eleven patients
presented with persistent or recurrent local disease, eight with
regional disease and three with distant metastases. At 5 years,
actuarial locoregional control was 73% (95% CI 60-85%),
actuarial disease-free survival was 69% (95% CI 56-82%) and
overall survival was 67% (95% CI 54-81%).
Correlation of Mib 1 index with different end points
The mean Mib-1 index for all patients was 56.2% (±17.88%) with
a median of53% (range 18-96%). In the absence of an established
cut-offfor the Mib- 1 index in anal carcinoma, the median value of
the indices was used to establish two groups, one with a high
(>53%) and the other with a low (<53%) index. These two groups
(high vs low index) were found to be similar regarding the 5-year
overall survival (64% vs 69%, P = 0.7), locoregional control (77%
vs 69%, P = 0.5) and disease-free survival (73% vs 66%, P = 0.5).
These results reflect the fact that the mean value of the Mib-1
index in 39 patients without any failure was similar to the corre-
sponding value in the 16 patients who presented with any compo-
nent offailure (57% vs 54%, P = 0.56).
Correlation between Mib-1 index and
clinicopathological parameters
Because some clinical factors have been reported to be of prog-
nostic value (Salmon et al, 1986; Goldman et al, 1987; Touboul et
al, 1994; Allal et al, 1997), correlations of these parameters with
Mib- 1 indices were studied to assess potential linkage. In addition,
a univariate analysis ofthe present series was undertaken to deter-
mine which clinical or therapeutic factors were significantly asso-
ciated with a decrease in locoregional control. The only parameter
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Table 2 Correlation of Mib-1 index and clinical parameters
No. of patients
N-stage
No/N1-3
Gender
Male/female
Age
< 65/ > 65 years
Tumour location
Canal/canal and or margin
Histology
Squamous/basaloid or transitional
T-stage
T1-2fT3-4
Tumour extent
< 1/3 circumference/ > 1/3
43/11
15/40
28/27
42/13
32/23
34/21
24/31
reaching a statistically significant level (P <0.05) was lymph node
involvement, whereas tumour extension over more than one-third
ofthe circumference was ofborderline significance (P = 0.07). No
therapeutic factors reached a significant level.
Correlation of the Mib-I index with lymph node status
suggested a lower mean value in patients with clinical node
involvement, but this was not significant (49% vs 58%, P = 0.12).
Also, no significant association was found between Mib-1 mean
values and the remaining clinicopathological parameters studied
(Table 2).
DISCUSSION
As is the case for many cancers, prognostic indicators of patient
outcome in anal carcinomas have traditionally been derived from
clinical features, based essentially on tumour extension as
expressed by T-stage or amount of circumferential involvement.
Moreover, other clinicopathological parameters such as gender,
age, tumour location, lymph node involvement and histological
subtype are not unanimously recognized as influencing outcome
(Salmon et al, 1986; Papillon and Montbarbon, 1987; Cummings
et al, 1991; Touboul et al, 1994). These carcinomas have the pecu-
liarity of being essentially a locoregional disease, the success of
treatment depending principally on obtaining local and regional
control. As current sphincter-conserving approaches fail to control
up to one-third of anal carcinomas, there is a need for continued
research to identify additional prognostic factors that may allow
development ofindividualized strategies.
Recently, ithas been proposed thattherate oftumourcell prolif-
eration may be a determining factor in the clinical outcome of
many cancerpatients (Riley, 1992). Several studies have found the
Mib-1 index or the Ki-67 labelling index to have potential prog-
nostic value in various malignant diseases. Thus, Pinder et al
(1995), in a series of 177 patients with breast carcinoma, found the
Mib-1 index to be strongly associated with histological grade,
tumour size and patient survival (P = 0.001), and to be signifi-
cantly correlated with survival in a multivariate analysis. Railo et
al. (1993) reported similar conclusions in a series of 327 breast
cancer patients. A positive correlation between high Ki-67 index
and poor prognosis has also been reported for upper urinary tract
carcinomas (Chowdhury et al, 1996), astrocytomas (Wakimoto
Mean values (%)
58/49
61/54
58/53
54/60
57/55
55/57
55/56
p
0.12
0.2
0.25
0.3
0.6
0.7
0.8
et al, 1996) and hepatocellular carcinomas (Ng et al, 1995).
However, inconclusive or contradictory results have been reported
for certain other tumour types, namely oesophageal squamous cell
carcinomas (Youssefet al, 1995; Sarbia et al, 1996), gastric carci-
nomas (Yonemura et al, 1991; Muller et al, 1996) and lung carci-
nomas (Pence et al, 1993; Pujol et al, 1996), and several studies
showed no predictive value of the Ki-67 index in cervical carci-
nomas (Cole et al, 1992; Levine et al, 1995; Oka and Arai, 1996).
In the present study of 55 patients with anal carcinoma treated
by radiotherapy, no correlation could be demonstrated between the
Mib-1 index and the three end points studied (locoregional control,
disease-free survival and overall survival), nor could any associa-
tion be shown with clinical parameters such as age, gender,
primary tumour extent and location, lymph node involvement and
histological subtype. However, the weaknesses of such a limited
retrospective study require that these results be interpreted with
caution. Firstly, problems inherent to immunohistochemical
studies of archival paraffin-embedded material deserve mention,
including the questions of the effect of long-term storage on
antigen stability and the potential sampling bias related to varia-
tions in the Mib-1 index throughout the tumour specimen.
Secondly, the present study is basedon a subsetofalargerseries of
patients treated during the same time period, with a correspond-
ingly small number of events forming the basis for the analysis.
However, the selection of patients for this study was biased only
by the availability ofadequate paraffin blocks, and the characteris-
tics and clinical outcome of these patients were essentially iden-
tical to those of patients in the larger series (Allal et al, 1997).
Nonetheless, even taking those remarks into consideration, our
results suggest that the Mib-1 index is of little prognostic value,
particularly considering the fact that the median values in patients
with and without failure are essentially identical (52% vs 54%).
As this report is the first to evaluate the Mib-l index in a rela-
tively large series of patients with this uncommon disease, no
meaningful comparison with the results ofother series is possible.
Nonetheless, it is worthwhile mentioning that the inability of the
Mib-1 index to predict patient outcome in anal carcinoma is in
keeping with the negative findings reported in squamous cell
carcinomas of the uterine cervix, a disease that shares certain
common morphological, epidemiological and therapeutic aspects
with carcinomas ofthe anal region.
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An additional original finding of this study concerns the high
Mib-1 indices encountered in anal carcinomas. Indeed a median
value of 53% (mean value of 56%) represents one of the highest
indices reported in the literature for an epithelial cancer. Our
results are compatible with the high proliferating cell nuclear
antigen indices (means ranging from 66% to 83%) reported by
Noffsinger et al (1994) in a series of 34 anal carcinomas, and are
consistent with the demonstration by Goldman et al (1987) of
tumour aneuploidy in most anal carcinoma specimens studied.
Moreover, this high Mib-1 index may shed light on the remark-
able radio- and chemosensitivity of these carcinomas. Indeed,
Willett et al (1995) reported a marked pathological downstaging
after preoperative irradiation of rectal adenocarcinomas with
higher Ki-67 index compared with tumours with low indices. In
addition, although not confirmed by others, Hall et al (1988)
observed that patients with high-grade lymphomas having Ki-67
indices greater than 80% had a better survival than those with
lower indices, suggesting that rapidly proliferating lesions are
more chemosensitive.
In conclusion, the Mib-1 index failed to predict locoregional
control or survival in patients with anal carcinomas treated conser-
vatively by radiotherapy with or without chemotherapy. On the
other hand, the Mib-1 indices observed in this study were among
the highest reported for tumours ofepithelial origin. These results
merit confirmation by other investigators before drawing defini-
tive conclusions.
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